These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29879685)

  • 1. Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales.
    Crosland P; Maconachie R; Buckner S; McGuire H; Humphries SE; Qureshi N
    Atherosclerosis; 2018 Aug; 275():80-87. PubMed ID: 29879685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
    Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
    Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
    McKay AJ; Hogan H; Humphries SE; Marks D; Ray KK; Miners A
    Atherosclerosis; 2018 Aug; 275():434-443. PubMed ID: 29937236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.
    Haralambos K; Whatley SD; Edwards R; Gingell R; Townsend D; Ashfield-Watt P; Lansberg P; Datta DB; McDowell IF
    Atherosclerosis; 2015 May; 240(1):190-6. PubMed ID: 25797312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis.
    Qureshi N; Woods B; Neves de Faria R; Saramago Goncalves P; Cox E; Leonardi Bee J; Condon L; Weng S; Akyea RK; Iyen B; Roderick P; Humphries SE; Rowlands W; Watson M; Haralambos K; Kenny R; Datta D; Miedzybrodzka Z; Byrne C; Kai J
    Health Technol Assess; 2023 Oct; 27(16):1-140. PubMed ID: 37924278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
    Pelczarska A; Jakubczyk M; Jakubiak-Lasocka J; Banach M; Myśliwiec M; Gruchała M; Niewada M
    Atherosclerosis; 2018 Mar; 270():132-138. PubMed ID: 29407882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
    Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
    Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic diagnosis of familial hypercholesterolaemia using a rapid biochip array assay for 40 common LDLR, APOB and PCSK9 mutations.
    Martin R; Latten M; Hart P; Murray H; Bailie DA; Crockard M; Lamont J; Fitzgerald P; Graham CA
    Atherosclerosis; 2016 Nov; 254():8-13. PubMed ID: 27680772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome.
    Amor-Salamanca A; Castillo S; Gonzalez-Vioque E; Dominguez F; Quintana L; Lluís-Ganella C; Escudier JM; Ortega J; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    J Am Coll Cardiol; 2017 Oct; 70(14):1732-1740. PubMed ID: 28958330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK.
    Kerr M; Pears R; Miedzybrodzka Z; Haralambos K; Cather M; Watson M; Humphries SE
    Eur Heart J; 2017 Jun; 38(23):1832-1839. PubMed ID: 28387827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the Detection of Potential Cases of Familial Hypercholesterolemia: Could Machine Learning Be Part of the Solution?
    Stevens CAT; Vallejo-Vaz AJ; Chora JR; Barkas F; Brandts J; Mahani A; Abar L; Sharabiani MTA; Ray KK
    J Am Heart Assoc; 2024 Jun; 13(12):e034434. PubMed ID: 38879446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia.
    Chan DC; Pang J; Hooper AJ; Bell DA; Bates TR; Burnett JR; Watts GF
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1704-1714. PubMed ID: 29408959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel LDLR disease-causing variant using capture-based next-generation sequencing screening of familial hypercholesterolemia patients in Taiwan.
    Hsiung YC; Lin PC; Chen CS; Tung YC; Yang WS; Chen PL; Su TC
    Atherosclerosis; 2018 Oct; 277():440-447. PubMed ID: 30270083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Founder effects facilitate the use of a genotyping-based approach to molecular diagnosis in Swedish patients with familial hypercholesterolaemia.
    Benedek P; Jiao H; Duvefelt K; Skoog T; Linde M; Kiviluoma P; Kere J; Eriksson M; Angelin B
    J Intern Med; 2021 Aug; 290(2):404-415. PubMed ID: 33955087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing and Optimizing Innovative Tools to Address Familial Hypercholesterolemia Underdiagnosis: Identification Methods, Patient Activation, and Cascade Testing for Familial Hypercholesterolemia.
    Campbell-Salome G; Jones LK; Masnick MF; Walton NA; Ahmed CD; Buchanan AH; Brangan A; Esplin ED; Kann DG; Ladd IG; Kelly MA; Kindt I; Kirchner HL; McGowan MP; McMinn MN; Morales A; Myers KD; Oetjens MT; Rahm AK; Schmidlen TJ; Sheldon A; Simmons E; Snir M; Strande NT; Walters NL; Wilemon K; Williams MS; Gidding SS; Sturm AC
    Circ Genom Precis Med; 2021 Feb; 14(1):e003120. PubMed ID: 33480803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part.
    Brett T; Qureshi N; Gidding S; Watts GF
    Atherosclerosis; 2018 Oct; 277():399-406. PubMed ID: 30270077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families.
    Truong TH; Kim NT; Nguyen MNT; Pang J; Hooper AJ; Watts GF; Do DL
    Atherosclerosis; 2018 Oct; 277():392-398. PubMed ID: 30270076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DIAgnosis and Management Of familial hypercholesterolemia in a Nationwide Design (DIAMOND-FH): Prevalence in Switzerland, clinical characteristics and the diagnostic value of clinical scores.
    Miserez AR; Martin FJ; Spirk D
    Atherosclerosis; 2018 Oct; 277():282-288. PubMed ID: 30270060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?
    Page MM; Bell DA; Watts GF
    Clin Genet; 2020 Apr; 97(4):543-555. PubMed ID: 31833051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.